Canfield Scientific Inc. succeeded in getting parts of a patent covering a device to detect skin cancer declared invalid at the Federal Circuit on Thursday, after originally losing on its claims at the Patent Trial and Appeal Board.
Canfield challenged Melanoscan LLC’s U.S. Patent No. 7,359,748, which covers a system to detect, diagnose, and treat skin cancer using an “enclosure fitted with cameras and lights” to scan a subject’s body.
It argued parts of the patent were invalid based on a combination of earlier publications that disclosed similar inventions. Canfield said that, to come up with the patented invention, a ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.